In the News

1857 News Items found
Vice President Joseph Biden visited Memorial Sloan Kettering Cancer Center (MSK) for a roundtable discussion with MSK experts and members of the cancer community. The candid conversation, inspired by the “moonshot” initiative announced by President Obama, was led by Craig Thompson, MD, President and CEO of MSK. MSK’s Carol Brown, MD, Ross Levine, MD, and Robert Sidlow, MD, were also active participants in the discussion. For more information about the event or to request an interview with a MSK roundtable participant, please e-mail [email protected].
The lack of participation in clinical research may be the Achilles heel facing today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of MSK, only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. For more information or to schedule an interview, please contact [email protected].
A young female doctor in a white coat sits with an older male patient in an exam room
Finding
Most people are aware of how important clinical trials for cancer are and how they can lead to lifesaving breakthroughs, but they’re also unlikely to participate in them.
A Hodgkin lymphoma survivor who received nivolumab as part of a clinical trial.
In the Clinic
The immunotherapy drug nivolumab is now approved for patients whose Hodgkin lymphoma has failed other treatments.
DNA molecules wrapped around histones
Feature
Discover some of the most exciting research that Memorial Sloan Kettering scientists are pursuing in the fight against cancer.
author finds help for chemo brain
Feature
Is Chemo Brain Real?
Cancer treatments like chemotherapy may cause cognitive changes, which experts call “chemo brain.” Learn how Memorial Sloan Kettering experts help patients with this condition.
Vice President Joe Biden addressed members of the American Association for Cancer Research on Wednesday in New Orleans.
In the News
The 2016 annual meeting of the American Association for Cancer Research (AACR) ended with a visit from the Vice President.
José Baselga
Announcement
At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.
Dr. Joan Massagué, Sloan Kettering Institute Director received the Pezcoller Foundation-AACR International Award for Cancer Research and was named an AACR fellow at AACR16.
Announcement
Long-awaited results of clinical trials testing targeted drugs and immunotherapy combinations were on offer at the annual American Association for Cancer Research (AACR) conference.
Memorial Sloan Kettering experts are available to comment on new research presented at the American Association for Cancer Research 2016 Annual Meeting including immunotherapy and CAR T cells, exercise oncology, precision medicine and more. For more information and to set up interviews or access photos, email Nicole H. McNamara at [email protected].